Annual report pursuant to Section 13 and 15(d)

Background and Organization (Details)

v3.22.0.1
Background and Organization (Details)
12 Months Ended
Dec. 21, 2020
USD ($)
shares
Dec. 16, 2020
D
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
Dec. 31, 2020
USD ($)
Dec. 21, 2021
$ / shares
shares
Subsidiary, Sale of Stock [Line Items]          
Share price | $ / shares     $ 10.00    
Warrants to purchase shares | shares   172,500     172,500
Warrants exercise price | $ / shares   $ 12.50     $ 12.50
Warrants exercise price percentage of IPO Price   125.00%      
Net loss     $ 15,960,268 $ 10,346,395  
Net cash used in operating activities     15,689,578 3,895,195  
Accumulated deficit     $ 43,925,373 $ 27,965,105  
Minimum          
Subsidiary, Sale of Stock [Line Items]          
period in which the company has to raise additional capital to complete clinical development     13 months    
Maximum          
Subsidiary, Sale of Stock [Line Items]          
period in which the company has to raise additional capital to complete clinical development     18 months    
IPO          
Subsidiary, Sale of Stock [Line Items]          
Shares issued | shares 3,450,000 3,000,000      
Share price | $ / shares   $ 10.00      
Gross proceeds $ 34,500,000        
Net proceeds $ 31,100,000        
Underwriter option          
Subsidiary, Sale of Stock [Line Items]          
Shares issued | shares   450,000      
Days to purchase additional shares granted to underwriters | D   45